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Zoonotic diseases such as brucellosis have a major impact on the health and economic prosperity of 
the developing world. Recent advances in our understanding of brucellosis and new developments in 
diagnostics and vaccine technology provide unique opportunities for biotechnology companies in 
developing countries to make an essential contribution to the control of this disease. 
 





Health of both human and animal population is pivotal 
recognised for economic development, prosperity and 
stability. The burden of infectious diseases affects health 
and reproductivity of livestock, thereby greatly reducing 
its value and opportunities for trade. Zoonotic diseases 
like brucellosis are not only of veterinary importance but 
may also severely affect human health, contributing to 
morbidity and reduction of working capacity with 
concomitant loss of income. Brucellosis has been 
reported from almost all countries in Africa (Refai, 2002). 
A recent study identified brucellosis in sub-Saharan 
Africa as a major priority for control and prevention 
through its impact on multiple livestock species including 
cattle, goats, sheep and pigs, its widespread distribution 
and its debilitating effect on man (Perry et al., 2002).  
Brucellosis is prevalent in all major livestock production 
systems in sub-Saharan Africa, yet its presence often 
remains unrecognised through lack of awareness by both 
veterinarians and health care staff and absence of 
accessible laboratory diagnostic facilities. As a 
consequence brucellosis remains a largely neglected 
disease with little attention to control and prevention 
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has been instigated (McDermott and Arimi, 2002). This is 
based on vaccination programmes combined with test 
and slaughter policies (Emslie and Nel, 2002). 
Preliminary data suggests that the incidence of 
brucellosis is highest in pastoral production systems 
where large numbers of animals mix and lowest for 
confined farms. Bovine brucellosis seems to be more 
common than ovine brucellosis, however this may be an 
artifact reflecting the serological testing of livestock 
species. Much less is known of the prevalence in man 
and of the effect on human health in this region of the 
world. Provision of improved diagnostics is crucial to 






Brucellosis is one of the most important bacterial 
zoonosis worldwide (Young, 1995). The aetiological 
agents are gram-negative coccobacillae belonging to the 
genus Brucella. Brucella melitensis, B. abortus and B. 
suis have small ruminants, cattle, and pigs respectively 
as their principle hosts. Transmission from infected 
livestock to man can either be direct through contact with 
infected material, or indirect through consumption of 
animal produce. The epidemiology of brucellosis is 
complex.   Important   factors   that    contribute    to    the  
  




prevalence and spread in livestock include farming 
system and practices, farm sanitation, livestock 
movement, mixing and trading of animals, and sharing of 
grazing grounds (Kadohiri et al., 1997; Omer et al., 2000; 
Kabagambe et al., 2001). Further complications arise 
through wild animal reservoirs which may also carry and 
transmit the disease (Godfroid, 2002). Brucella has a low 
infectious dose (10 organisms of B. melitensis are 
sufficient to cause infection in man), making infection a 
genuine risk to those occupationally exposed such as 
farmers, veterinarians and butchers and to the public 
through the consumption of contaminated unprocessed 
milk, milk products and meats. Abortion materials 
characteristically contain high numbers of brucellae and 
consequently pose significant infection risks if not 
properly handled and disposed of. Similarly, 
environmental contamination contributes to further 
spread among animals. Infected non-pregnant livestock 
may not demonstrate clinical signs of infection, which 
together with the complex epidemiology makes the 
control and prevention of this disease challenging. 
In livestock, Brucella results in abortion, reduced fertility 
and weak offspring. In addition, other more specific 
problems such as hygromas in cattle, or orchitis and 
spondylitis may be seen in swine. In man, the disease 
may affect almost any organ and causes a variety of 
problems, which if not treated early may lead to severe 
and prolonged disability (Corbell, 1997). Illness caused 
by B. melitensis generally is more prolonged and more 
severe and debilitating than illness caused by B. abortus 





Diagnosis of brucellosis however is often difficult to 
establish, largely through similarity with clinical 
presentations of other infections prevalent in sub-
Saharan Africa such as malaria. Therefore laboratory 
testing is an absolute prerequisite for a proper diagnosis 
of human brucellosis and for detection and confirmation 
of brucellosis in animals. Laboratory diagnosis of 
brucellosis in animals or man may be achieved either 
through blood culture or serological testing. Cultivation 
requires containment level three facilities that are rarely 
available in developing countries while classical 
serological tests may give inconsistent results when not 
performed by experienced staff. Poor reproducibility has 
been demonstrated with a frequently used serological 
screening test, the Rose Bengal test (RB), when 
performed at different study sites (Maichomo et al., 
1998). Specificity issues have also plagued the RB test. 
Consequently, positives should be confirmed in a more 
specific test such as the serum agglutination test, 
complement fixation test, or the enzyme linked 
immunosorbent assay (Omer et al., 2001; Al Dahouk et 
al., 2003).   These assays ideally should be done in a 





diagnostic developments such as hand-held polymerase 
chain reaction machines offer promising new 
opportunities for the development of both bed-side 
diagnostics and pen-side tests for brucellosis (Emanuel 
et al., 2003). New developments in serological test 
design already have led to new diagnostic tests for 
human brucellosis (Orduna et al., 2000; Smits et al., 
2003). Of these the Brucella IgM/IgG flow assay for the 
serodiagnosis of human brucellosis is specifically 
designed for user-friendliness and speed (Smits et al., 
2003; Irmak et al., 2004), and potentially can be 





Although controlled or eradicated in a number of 
developed countries, re-introduction of brucellosis 
remains a constant threat, while in others, especially in 
the developing world, this disease continues to exert its 
devastating impact perpetuating poverty. Despite 
tremendous efforts and financial investments, many 
European Mediterranean countries have yet to eradicate 
this disease. Many factors, in particular the types of 
husbandry system, may have contributed to the failure to 
effectively control the disease in these countries. The re-
emergence of brucellosis as a major veterinary and 
public health problem in the former Soviet Republic 
during the past decade through a weakening of the 
veterinary system and transition from large government 
controlled farms to small-scale private farming, further 
emphasises the essential role of a continued and co-
ordinated control effort. The transmission and spread of 
brucellosis is affected by a variety of factors and good 
knowledge of these is essential to the success of a 
control policy (Reviriego et al., 2000; Bikas et al., 2003; 
Minas et al., 2004). In general, prevalence of brucellosis 
usually is higher and control more problematic in pastoral 
or migratory populations, practiced by a significant 
proportion of the agricultural population of Africa.  
Vaccination of livestock is crucial to the control of 
brucellosis. Effective reduction of disease prevalence in 
livestock through mass vaccination eventually will also 
lead to a reduction of brucellosis in the human 
population. However, vaccination alone is not sufficient 
and should be accompanied by other measures such as 
restriction of animal movement and trade, culling of 
infected animals and improved farm sanitation to reduce 
the further spread of disease. In addition, a surveillance 
system is essential to control the efficacy of control 
measures and to identify outbreaks at an early stage. 
Clearly the control of brucellosis requires significant 
efforts both in terms of human and financial resources 
and time. In Argentina and other countries in South and 
Central America, brucellosis has been recognised as a 
disease problem since the 19th century, but  in spite  of 
control efforts starting in Argentina in 1932, the disease 






(Samartino, 2002). Despite the bleak situation outlined 
above, in resource poor countries control measures 
provided that they are adapted to the local situation and 
supported by the local population and instigated together 
with improved diagnostics, could provide immediate cost-
effective benefits (Roth et al., 2003). Demonstration of 
the cost-effectiveness of control measures is an essential 
prerequisite to gain acceptance and sustainability of such 
efforts.  
Veterinary vaccines for brucellosis are available for 
brucellosis in cattle and in small ruminants (Schurig et al., 
2002). The attenuated live B. abortus S19 vaccine is the 
recommended vaccine for bovine brucellosis (Nicoletti, 
1990). The attenuated live B. melitensis Rev-1 vaccine is 
recommended for goats and sheep (Elberg and Faunce, 
1957).  These attenuated strains are still smooth and 
consequently their use results in positive serology that 
can be confused with naturally infected animals. The live 
rough strain B. abortus 45/20 reverts to virulence in vivo 
and was subsequently used as a killed vaccine.  
Protective effect was limited and consequently its use 
should be avoided. Newly developed vaccines such as 
the B. abortus RB51 vaccine provide promising 
alternatives but require more extensive field studies and 
experience to establish its safety and efficacy. A safe and 
effective vaccine for brucellosis in man does not exist 
despite considerable efforts. 
 
 
SUSTAINABLE DISEASE MANAGEMENT 
 
Ideally, effective control of brucellosis should be through 
a combination of improved diagnosis, vaccination and 
treatment, together with measures to increase 
awareness, and improved farm sanitation and food 
hygiene. Collectively these will increase the effect of 
control measures and lessen the burden of disease. An 
integrated disease education and community participation 
program may assist achievement of this goal. Traditional 
beliefs and habits may interfere with disease prevention 
and prohibit its acceptance due to lacunas in disease and 
health knowledge. Awareness of the cause of this 
disease and knowledge of measures for prevention and 
resulting benefits of this can be provided through such a 
program, creating a positive attitude towards disease 
prevention. A disease education and community 
participation program will promote involvement, 
encourage acceptance thereby increasing the efficacy of 
control measures. For instance, in the absence of a 
strong government and means of enforced vaccination, 
the instigation of other control measures will depend in 
the voluntary acceptance from livestock owners. They 
may not be willing, or reluctant to co-operate in the 
absence of incentives or awareness of health and 
financial benefits. Disease education will provide 
information on the benefits of disease control and 
stimulate  community  participation.  Good  knowledge  of   




local factors contributing to the spread and transmission 
of the disease is vital when evaluating the effectiveness 
of the disease control measures. This can be obtained 
through epidemiological investigations and interviewing 
healthcare workers, veterinarians and risk groups. 
Recently McDermott and Arimi (2002) summarised 
epidemiological findings for brucellosis in sub-Saharan 
Africa. Brucellosis is common in cattle but less well 
studied in small ruminants. Bovine brucellosis prevalence 
rates ranging from 3.3% for the Central African Republic 
(Nakoune et al., 2004) to as high as 41% for Togo have 
been reported (Domingo, 2000). Values falling within this 
range were reported for Chad (Schelling et al., 2003), 
Sudan (El-Ansary et al., 2001), Eritrea (Omer et al., 
2000), Tanzania (Weinhaupl et al., 2000), Burkina Faso 
(Coulibaly and Yameogo, 2000), Ghana (Turkson and 
Boadu, 1992; Kubuafor et al., 2000), Mali (Tounkara et 
al., 1994), Nigeria (Ocholi et al., 1996) and Zimbabwe 
(Mohan et al., 1996). In goats, a prevalence of 4% has 
been reported from Sudan (El-Ansary et al., 2001), while 
in Uganda 2% were positive (Kabagambe et al., 2001). 
Herd prevalence is usually higher. 
Human brucellosis has been poorly studied in Africa. 
Seroprevalence of 3.8% has been reported in nomadic 
pastoralists from Chad (Schelling et al., 2003). 
Occupational contacts, including butchers, 
slaughterhouse workers, milkers, and cow attendants in 
one state in eastern Sudan revealed 1% were infected 
(El-Ansary et al., 2001). In contrast, slaughterhouse 
workers in Djibouti gave 6.5% positive (Chantal et al., 
1996) and high-risk groups from Eritrea showed a 
seroprevalence between 3.0% and 7.1% (Omer et al., 
2002). Studies of febrile patients in a large hospital in 
Kampala, the capital of Uganda, yielded 13.3% 
(Mutanda, 1998), while in eastern Nigeria 5.2% were 
seropositive (Baba et al., 2001).  
More detailed investigations have shown that the 
seroprevalence of brucellosis in cattle is closely related to 
the husbandry system with greatest risk for dairy cattle 
associated with mixed-breed herds in the state of Asmara 
in Eritrea (Omer et al., 2000). Other risks included use of 
hired caretakers, keeping sheep in addition to goats, free 
browsing for goat herds in eastern and western Uganda 
(Kabagambe et al., 2001), and features of pastoral 
managements such as extensive grazing for cattle herds 
in Kenya (Kadohira et al., 1997). Factors like nomadism, 
traditionalism with as an example sharing of males for 
breeding purpose. Education level and disease 
knowledge, animal trade and vaccination status have 
been identified in other studies (Mikolon et al., 1998; 
Lithg-Pereira et al., 2003). The transmission and the risk 
of disease in the human population is generally closely 
related to the presence of brucellosis in livestock, 
professional engagement with animal raising and food 
production and sanitairy conditions at the working place 
or food hygiene and food habits. Risk factors for having 
brucellosis have  been  investigated in  detail  in  different 
  




countries (Bikas et al., 2003; Al-Shamahy et al., 2000; 
Gotuzzo et al., 1987). 
Clearly the epidemiological information and our 
understanding of brucellosis in Africa are growing. Major 
lacunas in our knowledge are the presence of brucellosis 
in small ruminants, the significance of human brucellosis 
and the relative contributions of the various animals 
species to infection in man. Nevertheless, the available 
information highlights the urgent need for a control policy 
to drastically curtail the negative public health and 
economic effects of this disease. The impact of 
brucellosis affects both public health and livestock, 
consequently, effective control is best delivered through a 
unified approach involving both medics, scientists and 
veterinarians. Co-ordination of both health scientists and 
veterinarians is crucial because although brucellosis 
affects human health and economic prosperity, as a 
zoonosis, control should target the disease reservoir in 
animals. Beyond those involved with livestock, those 
involved in processing animal produce such as milk need 
to adopt control measures such as pasteurisation. To be 
effectively achieved control measures will require full co-
operation and hence the benefits should be clearly 
demonstrated and communicated. Collectively, 
epidemiological information together with demonstration 
of the cost-effectiveness of brucellosis control, can be 
used to set priorities and influence policy. 
 
 
FUTURE DEVELOPMENTS IN DIAGNOSTICS 
 
Biotechnology can make important contributions to the 
control and prevention of brucellosis. First, there is an 
urgent need for affordable, rapid (bed-side and pen-side) 
diagnostics permitting decentralised brucellosis testing. 
Secondly, there is a need for cheap and well-validated 
vaccines that do not interfere with diagnostic tests. At 
present, diagnostic testing is often not performed 
because expertise and laboratory facilities are not 
available or laboratory testing is performed, but with 
considerable delay through requirements to submit 
samples to a central laboratory with results being 
available often only after days or even weeks. Diagnostic 
delays results in increased opportunities for spread of 
disease, hampering control efforts. New developments in 
test design and format such as fluorescent-polarization 
based assays (Dajer et al., 1999; Nielsen et al., 2001), 
polymerase chain reaction based assays (Al Dahouk et 
al., 2004), electronic noses (Pavlau and Turner, 2000; 
Turner and Magan, 2003) and lateral flow assay devices 
(Smits et al., 2003), provide new opportunities for the 
development of simple, rapid and affordable tests for 
infectious diseases that may be used outside the 
established laboratory. These developments provide new 
opportunities for biotechnical companies in developing 






VACCINES – POBLEMS AND PITFALLS 
 
Existing vaccines induce high antibody levels against the 
lipopolysaccharide antigens of brucellae, which are the 
basis of serodiagnostic assays, consequently resulting in 
positive serological tests. A rough vaccine strain based 
on the rifampicin-resistant mutant B. abortus RB51 does 
not have this problem, however, its efficacy in non-bovine 
species has been questioned. Vaccine production in 
developing countries provides an important role for 
biotechnology companies. Furthermore, with the 
availability of genome sequences (DelVechio et al., 
2002a; Paulsen et al. 2002) the prospect of the 
development of an effective acellular vaccine has 
become a step closer. Here the challenge is to provoke a 
good Th1 response that will result in protective immunity. 
Post-genomic approaches may also help with selection of 
better antigens for test development, possibly able to 
distinguish between immune responses following either 
natural infections or vaccination (DelVechio et al., 2002b; 
DelVechio et al., 2002c). Biotechnology entrepreneurship 
is rapidly growing in the developing world and offers a 
means of making a real contribution to the economic 





Accumulating epidemiological evidence emphasises the 
need for brucella control in sub-Saharan Africa. Control of 
brucellosis in other situations has highlighted the 
importance of detailed knowledge of local epidemiology 
and community support for effective control. 
Demonstration of the cost-effectiveness of control is 
essential to underpin policy changes and full community 
participation. Being a zoonosis, vaccination of livestock is 
pivotal in the control of this disease. Existing vaccines are 
beneficial, but also have problems, however, these can 
be successfully used in control programs. New 
knowledge and biotechnological developments bring an 
effective acellular vaccine a step closer. Similar 
technological advances have enabled the development of 
simple, rapid and user-friendly diagnostics suitable for 
de-centralised testing. De-centralised testing is essential 
for rapid diagnosis and early instigation of disease control 
measures. This could also offer sensitivity and specificity 
permitting enhanced monitoring and surveillance in 
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